FeesSafety
Pluang+

Erasca upgraded to Buy as ERAS-0015 shows strong cancer trial results and patent issues ease.

Analyst Insights
20 Nov 2026, 17:53 WIB
Seeking Alpha
View Source
Bullish
Erasca upgraded to Buy as ERAS-0015 shows strong cancer trial results and patent issues ease.

Erasca has been upgraded from Hold to Buy following promising early trial results for its drug ERAS-0015, which showed unconfirmed response rates of 50% in pancreatic cancer and 64% in lung cancer. The company plans three registrational trials by 2027-2028 and is expanding its pipeline with ERAS-4001 targeting KRAS-mutated tumors and a collaboration with Bristol Myers Squibb for MTAP-deleted pancreatic cancer. The pancreatic cancer treatment market is projected to reach $12.6 billion by 2033, highlighting significant growth potential for Erasca's therapies.

Erasca's stock trades at USD 13.56 as of Nov 20, 2026 23:02 WIB, down 4.64% for the day and closer to its 52-week low of USD 2.78 than its high of USD 22.47. In contrast, Bristol-Myers Squibb shares are priced at USD 59.20, up 1.47%, and nearer to their 52-week high of USD 68.09 than the low of USD 45.94. Despite Erasca's recent upgrade, Pluang users hold Bristol-Myers Squibb much longer, with a typical hold time of 91 days versus 4 days for Erasca.

More News (ERAS)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App